Profile data is unavailable for this security.
About the company
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
- Revenue in USD (TTM)0.00
- Net income in USD-98.79m
- Incorporated2012
- Employees20.00
- LocationRelmada Therapeutics Inc2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES 33134United StatesUSA
- Phone+1 (646) 876-3459
- Websitehttps://www.relmada.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMV Pharmaceuticals Inc | 0.00 | -68.96m | 108.03m | 63.00 | -- | 0.4787 | -- | -- | -1.44 | -1.44 | 0.00 | 4.39 | 0.00 | -- | -- | 0.00 | -26.40 | -21.16 | -27.72 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Vigil Neuroscience Inc | 0.00 | -82.64m | 108.62m | 69.00 | -- | 0.8921 | -- | -- | -2.13 | -2.13 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -48.43 | -- | -51.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Sangamo Therapeutics Inc | 176.23m | -257.83m | 109.25m | 405.00 | -- | 1.13 | -- | 0.6199 | -1.46 | -1.46 | 1.01 | 0.4653 | 0.4843 | -- | 76.61 | 435,140.80 | -70.85 | -26.09 | -90.72 | -31.04 | -- | -- | -146.30 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 114.56m | 56.00 | -- | 1.34 | -- | 194.83 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 114.92m | 35.00 | 509.80 | 453.88 | -- | 46.08 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| FibroGen Inc | 147.75m | -284.23m | 115.39m | 486.00 | -- | -- | -- | 0.781 | -2.93 | -2.93 | 1.52 | -2.07 | 0.2859 | 0.4597 | 6.28 | 304,016.50 | -55.51 | -30.62 | -119.42 | -42.31 | 87.24 | 93.52 | -194.16 | -119.08 | 1.33 | -53.30 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Assertio Holdings Inc | 152.07m | -331.94m | 116.05m | 53.00 | -- | 0.8369 | -- | 0.7631 | -3.97 | -3.97 | 2.04 | 1.46 | 0.4343 | 1.04 | 3.27 | 2,869,227.00 | -94.80 | -21.51 | -129.77 | -32.05 | 82.36 | 88.68 | -218.28 | -62.10 | 1.43 | -- | 0.2182 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| Relmada Therapeutics Inc | 0.00 | -98.79m | 116.17m | 20.00 | -- | 1.36 | -- | -- | -3.28 | -3.28 | 0.00 | 2.84 | 0.00 | -- | -- | 0.00 | -78.89 | -- | -87.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -117.86m | 119.38m | 168.00 | -- | 0.7883 | -- | -- | -1.75 | -1.75 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -47.38 | -45.79 | -50.28 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -27.03m | 119.47m | 28.00 | -- | 2.42 | -- | -- | -0.5642 | -0.5642 | 0.00 | 0.7889 | 0.00 | -- | -- | 0.00 | -47.51 | -38.31 | -56.21 | -43.34 | -- | -- | -- | -- | -- | -6.33 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Immunic Inc | 0.00 | -93.61m | 120.71m | 77.00 | -- | 2.09 | -- | -- | -2.11 | -2.11 | 0.00 | 0.6404 | 0.00 | -- | -- | 0.00 | -102.84 | -72.09 | -129.79 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Coya Therapeutics Inc | 6.00m | -7.99m | 121.78m | 8.00 | -- | 3.37 | -- | 20.29 | -0.8219 | -0.8219 | 0.5906 | 2.47 | 0.2417 | -- | -- | 750,276.30 | -32.17 | -- | -39.17 | -- | -- | -- | -133.08 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Inotiv Inc | 585.17m | -33.21m | 123.02m | 1.96k | -- | 0.484 | 5.62 | 0.2102 | -1.29 | -1.29 | 22.73 | 9.85 | 0.6858 | 6.46 | 7.12 | 299,320.70 | -3.96 | -23.84 | -4.62 | -29.26 | 30.29 | 29.31 | -5.78 | -33.24 | 1.28 | 0.1431 | 0.5988 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Leap Therapeutics Inc | 0.00 | -81.41m | 123.21m | 54.00 | -- | 1.37 | -- | -- | -5.11 | -5.11 | 0.00 | 2.35 | 0.00 | -- | -- | 0.00 | -113.72 | -80.06 | -136.52 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 124.86m | 37.00 | -- | 1.01 | -- | 119.79 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
Data as of May 06 2024. Currency figures normalised to Relmada Therapeutics Inc's reporting currency: US Dollar USD
28.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 31 Dec 2023 | 2.04m | 6.78% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.30m | 4.31% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 1.18m | 3.92% |
| Parsons Capital Management, Inc.as of 31 Mar 2024 | 973.52k | 3.23% |
| Opaleye Management, Inc.as of 31 Dec 2023 | 877.00k | 2.91% |
| Palo Alto Investors LPas of 31 Dec 2023 | 732.40k | 2.43% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 565.60k | 1.87% |
| Two Sigma Advisers LPas of 31 Dec 2023 | 328.30k | 1.09% |
| Two Sigma Investments LPas of 31 Dec 2023 | 302.74k | 1.00% |
| Point72 Asset Management LPas of 31 Dec 2023 | 250.00k | 0.83% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
